In SelfPOCNAD, we propose to develop an industrial prototype for a rapid (“same day”) Cervical Cancer screening of self-taken patient samples. The industrial prototype will only include enough sample from the self-taken sample in order not to risk any clogging of the sample preparation chip. The first industrial prototype will include the detection of oncogenic E6/E7 mRNA from in total 9 HPV types with an option to detect up to 19 HPV types based on detection developed for Pre-Tect HPV-Proofer laboratory kit, Nucleic Acid Sequence Based Amplification. Introduction of SelfPOCNAD at Point of Care is expected to significantly improve compliance of women with Cervical Cancer screening programs Increased compliance of women with the ICC screening programs will drastically decrease the ICC incidence and save lives. ICC is the second most common cancer in women. Each year, there are over 470,000 new cases globally. Of these, 33,000 are in the EU. Once the disease is established, it is hard to cure, so each year 233,000 women die - 15,000 in the EU . After breast cancer, it is the second-most-common cancer amongst women. However, this is a preventable and treatable disease, if detected in the early stages. Some EU member states have well-organised screening and effective prevention programmes. But better compliance with screening, especially in New Member States could save the lives of 3-5,000 European women p.a.